Therefore, a combination chemotherapy regimen incorporating aspirin with ABT-737 warrants clinical investigation in solid tumours, and may potentially be an efficient therapy for aspirin-resistant PIK3CA wild-type tumours. This evidence concerns the gene PIK3CA and neoplasm.